|
Status |
Public on Jul 01, 2012 |
Title |
Simvastatin treated Lymphoblastoid Cell lines from Cholesterol and Pharmacogenomics (CAP) Trial |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Statins reduce cardiovascular disease risk by lowering plasma low density lipoprotein (LDL)-cholesterol. To identify novel pathways that modulate statin response, we assessed the influence of simvastatin exposure on expression quantitative trait locus (eQTL) associations across the genome in 480 lymphoblastoid cell lines (LCLs). Cell lines were derived blood samples collected ant entry visit from participants in the Cholesterol and Pharmacogenomics (CAP) trial, who underwent a 6 week 40mg/day simvastatin trial. We identified 4590 cis-eQTLS that were independent of treatment status (FDR=1%) and six cis-eQTLS for which there was evidence of an interaction with treatment (FDR=20%). Genotypes and Phenotypes derived from these indivudals are available through dbGaP (Accession Number). eQTL results are available at: http://eqtl.uchicago.edu/cgi=bin/gbrowse/eqtl/
|
|
|
Overall design |
Dataset consists of 960 expression beadarrays (Illumina HumanRef-8v3) representing paired samples derived from 24-hour exposures of 480 lymphoblastoid cell lines (LCLs) to 2 micromolar simvastatin acid or control buffer.
|
|
|
Contributor(s) |
Mangravite LM, Krauss RM |
Citation(s) |
24001602, 23935528, 23995691 |
Submission date |
Mar 28, 2012 |
Last update date |
Sep 11, 2019 |
Contact name |
Lara Mangravite |
E-mail(s) |
lara.mangravite@sagebase.org
|
Organization name |
Sage Bionetworks
|
Street address |
1100 Fairview Ave North
|
City |
Seattle |
State/province |
WA |
ZIP/Postal code |
98109-1024 |
Country |
USA |
|
|
Platforms (1) |
GPL6883 |
Illumina HumanRef-8 v3.0 expression beadchip |
|
Samples (960)
|
|
Relations |
BioProject |
PRJNA157039 |